Patents by Inventor John Wetzel
John Wetzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7473698Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: GrantFiled: July 3, 2003Date of Patent: January 6, 2009Assignee: H. Lunbeck A/SInventors: Mohammad R. Marzabadi, Yu Jiang, Kai Lu, Chien-An Chen, John E. De Leon, John Wetzel
-
Patent number: 7335665Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: GrantFiled: July 3, 2003Date of Patent: February 26, 2008Assignee: H - Lundbeck A/SInventors: Mohammad R. Marzabadi, Yu Jiang, Kai Lu, Chien-An Chen, John E. De Leon, John Wetzel, Kim Andersen
-
Publication number: 20070259942Abstract: This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.Type: ApplicationFiled: September 6, 2006Publication date: November 8, 2007Inventors: Thomas Blackburn, Michael Konkel, Lakmal Boteju, Ian Talisman, John Wetzel, Mathivanan Packiarajan, Heidi Chen, Hermo Jimenez
-
Publication number: 20070054910Abstract: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 23, 2006Publication date: March 8, 2007Inventors: Michael Konkel, John Wetzel, Jamie Talisman
-
Publication number: 20070043080Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 30, 2005Publication date: February 22, 2007Inventors: Mohammad Marzabadi, John Wetzel, John DeLeon, Yu Jiang, Chien-An Chen, Kai Lu
-
Publication number: 20060217418Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: ApplicationFiled: January 6, 2004Publication date: September 28, 2006Inventors: Mohammad Marzabadi, John Wetzel, Chien-An Chen, Yu Jiang, Kai Lu
-
Publication number: 20060173027Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: ApplicationFiled: July 3, 2003Publication date: August 3, 2006Applicant: H. Lundbeck A/SInventors: Mohammad Marzabadi, Yu Jiang, Kai Lu, Chien-An Chen, John De Leon, John Wetzel, Kim Andersen
-
Patent number: 7067534Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: November 21, 2003Date of Patent: June 27, 2006Assignee: H. Lundbeck A/SInventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Yu Jiang, Chien-An Chen, Kai Lu
-
Publication number: 20060084649Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: ApplicationFiled: January 6, 2004Publication date: April 20, 2006Applicant: Synaptic Pharmaceutical CorporationInventors: Mohammad Marzabadi, John Wetzel, Chien-An Chen, Yu Jiang, Kai Lu
-
Publication number: 20060041139Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: ApplicationFiled: January 14, 2003Publication date: February 23, 2006Inventors: Mohammad Marzabadi, John Wetzel, Chien-An Chen, Yu Jiang, Kai Lu
-
Publication number: 20050245743Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: ApplicationFiled: July 3, 2003Publication date: November 3, 2005Inventors: Mohammad Marzabadi, Jiang Yu, Kai Lu, Chien-An Chen, John De Leon, John Wetzel
-
Publication number: 20050192337Abstract: This invention relates to crystalline forms, as well as an amorphous form of Compound I [1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1H-indol-2-one], the processes for their preparation, compositions containing the same and the therapeutic use of such compositions. This invention further relates to a process for preparing Compound I.Type: ApplicationFiled: August 7, 2003Publication date: September 1, 2005Inventors: Vrej Jubian, John Wetzel, Michael O'Neill
-
Publication number: 20050154020Abstract: This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: ApplicationFiled: January 14, 2004Publication date: July 14, 2005Applicant: Synaptic Pharmaceutical CorporationInventors: Mohammad Marzabadi, John Wetzel, Chien-An Chen, John Deleon, Yu Jiang, Kai Lu
-
Publication number: 20050154022Abstract: This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.Type: ApplicationFiled: January 13, 2005Publication date: July 14, 2005Inventors: Mohammad Marzabadi, John Wetzel, Chien-An Chen, John DeLeon, Yu Jiang, Kai Lu
-
Publication number: 20050148635Abstract: This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.Type: ApplicationFiled: February 28, 2005Publication date: July 7, 2005Inventors: Michael Konkel, John Wetzel, Jamie Talisman
-
Publication number: 20040242609Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 15, 2004Publication date: December 2, 2004Applicant: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, John Wetzel, John E. Deleon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam
-
Patent number: 6727264Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: July 3, 2002Date of Patent: April 27, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Yu Jiang, Chien-An Chen, Kai Lu
-
Patent number: 6720324Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject.Type: GrantFiled: July 5, 2001Date of Patent: April 13, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam
-
Publication number: 20030144310Abstract: This invention provides a compound having the structure: 1Type: ApplicationFiled: September 24, 2002Publication date: July 31, 2003Inventors: Lakmal W. Boteju, Michael J. Konkel, Joel K. Kawakami, John Wetzel
-
Publication number: 20030139431Abstract: This invention provides compounds having the structure: 1Type: ApplicationFiled: September 21, 2002Publication date: July 24, 2003Inventors: Joel K. Kawakami, John Wetzel, Lakmal W. Boteju, Michael J. Konkel, Honghe Wan, Stewart A. Noble